Sana Biotechnology reports Q2 EPS (16c), consensus (21c)

Reports Q2 cash, cash equivalents, and marketable securities of $72.7M. The company notes that its pro forma Q2 cash position is $177.2M including gross proceeds from sales of common stock through its ATM and equity financing in July and August. The company expects its cash runway to last into the second half of 2026. “We are pleased with the progress with the type 1 diabetes program, including recent FDA feedback on our HIP-edited GMP master cell bank and non-clinical testing plan for SC451, positive UP421 6-month clinical results presented at an invited talk at the American Diabetes Association Annual Meeting and World Transplant Congress 2025, and UP421 3-month clinical results published in the New England Journal of Medicine,” said Steve Harr, Sana‘s President and CEO. “We expect to file the IND for SC451 as early as next year, and we also look forward to continuing progress in the rest of our pipeline. We have raised over $100 million in new capital since the end of the second quarter, strengthening our balance sheet and allowing us to continue to invest appropriately in moving our pipeline forward.”